KarXT: A New Era in Antipsychotics?
From Psychopharmacology and Psychiatry Updates · · 12 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
In this episode, we explore KarXT, a newly FDA-approved antipsychotic with a groundbreaking cholinergic mechanism, through the lens of a single powerful metric: the Number Needed to Treat. Could an NNT of 5 change how you approach treatment-resistant schizophrenia?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 80
- How Effective Is KarXT (Xanomeline-Trospium) for Schizophrenia? NNT and NNH Explained
Back to Psychopharmacology and Psychiatry Updates · Report a problem